Inflammatory Response Research Company
Inflammatory Response Research (“IRR”) is a drug development company focused on pharmaceutical products for the treatment of inflammatory disorders and conditions. Their initial product is an oral combination of levocetirizine (Xyzal) and montelukast (Singulair) at specific dosing for the treatment of influenza. Parallel research is focused on an intravenous (IV) preparation for the treatment of traumatic brain injury and severe cases of influenza. IRR was founded in 2011 and is headquartered in Santa Barbara, California.
Technology:
NeuroTech
Industry:
Biotechnology, Developer Platform, Health Care, Pharmaceutical
Headquarters:
Santa Barbara, California, United States
Founded Date:
2011-01-01
Employees Number:
1-10
Total Funding:
$1.8M
Estimated Revenue:
Less than $1M
Last Funding Type:
Venture - Series Unknown
Register and Claim Ownership